Updated results from AVENANCE: Real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment.

被引：10

作者：

Barthelemy, Philippe ^{[1
]}

Loriot, Yohann ^{[2
]}

Thibault, Constance ^{[3
]}

Gross-Goupil, Marine ^{[4
]}

Eymard, Jean Christophe ^{[5
]}

Voog, Eric ^{[6
]}

Abraham Jaillon, Christine ^{[7
]}

Le Moulec, Sylvestre ^{[8
]}

Chasseray, Matthieu ^{[9
]}

Gobert, Aurelien ^{[10
]}

Auberger, Benjamin ^{[11
]}

Viala, Caroline ^{[12
]}

Cabart, Mathilde ^{[13
]}

Kazan, Eyad ^{[14
]}

Lorgis, Veronique ^{[15
]}

Hilgers, Werner ^{[16
]}

Josse, Constant ^{[17
]}

Lambert, Prisca ^{[18
]}

Solbes, Marie-Noelle ^{[19
]}

Flechon, Aude ^{[20
]}

机构：

[1] Inst Cancerol Strasbourg Europe, Med Oncol, Strasbourg, France

[2] Inst Cancerol Gustave Roussy, Villejuif, France

[3] Univ Paris Cite, Hop Europeen Georges Pompidou, AP HP Ctr, Inst Canc Paris Carpem, Paris, France

[4] Bordeaux Univ Hosp, Bordeaux, France

[5] Inst Cancerol Jean Godinot, Reims, France

[6] Clin Victor Hugo, ILC Grp, Le Mans, France

[7] Foch Hosp, Serv Oncol Med, Suresnes, France

[8] Grp Radiotherapie & Oncol Pyrenees, Clin Marzet, Pau, France

[9] Clin Pasteur, Ctr Finisterien Radiothe & Oncol, Brest, France

[10] St Gregoire Hosp, St Gregoire, France

[11] CHRU Brest, Inst Cancerol & Hematol ICH Hop, Morvan, France

[12] CHU Nantes, Nantes, France

[13] Inst Bergonie, Bordeaux, France

[14] Clin Louviere, Ramsay Hlth Grp, Dept Med Oncol, Lille, France

[15] Inst Cancerol Bourgogne, Dijon, France

[16] Avignon Provence Canc Inst, Avignon, France

[17] Exystat, Malakoff, France

[18] Pfizer Oncol, Paris, France

[19] Merck Sante SAS, Merck KGaA, Lyon, France

[20] Ctr Leon Berard, Lyon, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

261-492-3532-2370-7650-2700; 283-183-138-12099; 130-540-543-12277; 261-566-148-11298; 8; 6; 3; 1880; 3590; 4044; 260; 112; 176; 3224; 65; 62; 295; 10; 2; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.561

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：561 / 561

页数：1

共 50 条

[1] AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
Barthelemy, P.
Loriot, Y.
Flechon, A.
Goupil, M. Gross
Voog, E.
Eymard, J-C.
Lorgis, V.
Pouessel, D.
Francois, L.
Sajous, C.
Bouju, D. Chocteau
Guillot, A.
Long, J.
Amela, E.
Josse, C.
Solbes, M-N.
Lambert, P.
Thibault, C.
ANNALS OF ONCOLOGY, 2023, 34 : S1211 - S1212
[2] Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
Barthelemy, Philippe
Loriot, Yohann
Voog, Eric
Eymard, Jean Christophe
Ravaud, Alain
Flechon, Aude
Jaillon, Christine Abraham
Chasseray, Matthieu
Lorgis, Veronique
Hilgers, Werner
Gobert, AurElien
Le Moulec, Sylvestre
Simon, Camille
Nicolas, Emanuel
Escande, Anne
Pouessel, Damien
Josse, Constant
Solbes, Marie-Noelle
Lambert, Prisca
Thibault, Constance
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[3] Subgroup analyses of patients (pts) with advanced urothelial carcinoma (aUC) who had long-term progression-free survival (PFS) or overall survival (OS) with avelumab first-line maintenance (1LM) in the AVENANCE real-world study
Barthelemy, P.
Eymard, J-C.
Flechon, A.
Goupil, M. Gross
Voog, E.
Loriot, Y.
Jaillon, C. Abraham
Gobert, A.
Chasseray, M.
Kazan, E.
Josse, C.
Lambert, P.
Paret, L.
Thibault, C.
ANNALS OF ONCOLOGY, 2024, 35 : S1151 - S1152
[4] Avelumab first-line maintenance (1LM) in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic: Interim real-world results from a national reimbursement registry.
Zemankova, Anezka
Studentova, Hana
Melichar, Bohuslav
Eid, Michal
Poprach, Alexandr
Kopecky, Jindrich
Spacek, Jan
Stuhlova, Sarka
Dvorak, Jan
Vlcek, Pavel
Zychackova, Katerina
Katolicka, Jana
Blazek, Tomas
Vrana, David
Majkova, Petra
Cepa, Adam
Fiala, Ondrej
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 557 - 557
[5] Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in the US.
Moon, Helen H.
Kearney, Mairead
Mahmoudpour, Seyed Hamidreza
Ike, Chiemeka
Morris, Valerie A.
Rava, Andrew
Kim, Sonia
Sun, Haiyan
Boyd, Marley
Rey, Gabriel Gomez
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 605 - 605
[6] Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment
Barthelemy, Philippe
Thibault, Constance
Flechon, Aude
Gross-Goupil, Marine
Voog, Eric
Eymard, Jean-Christophe
Abraham, Christine
Chasseray, Matthieu
Lorgis, Veronique
Hilgers, Werner
Gobert, Aurelien
Le Moulec, Sylvestre
Simon, Camille
Nicolas, Emanuel
Escande, Anne
Pouessel, Damien
Mouillet, Guillaume
Josse, Constant
Solbes, Marie-Noelle
Lambert, Prisca
Loriot, Yohann
EUROPEAN UROLOGY ONCOLOGY, 2025, 8 (02): : 407 - 416
[7] SPADE: Design of a real-world observational study of avelumab first-line maintenance (1LM) in advanced urothelial carcinoma in the Asia-Pacific region
Oliveira, Niara
Su, Po Jung
Park, Se Hoon
Tsai, Yu Chieh
Kim, Miso
Wu, Wen Jeng
Gao, Seasea
Shin, Sang Joon
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 97 - 97
[8] Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden
Bellmunt, Joaquim
Powles, Thomas
Park, Se Hoon
Voog, Eric
Valderrama, Begona Perez
Gurney, Howard
Ullen, Anders
Loriot, Yohann
Sridhar, Srikala S.
Tsuchiya, Norihiko
Sternberg, Cora N.
Aragon-Ching, Jeanny B.
Petrylak, Daniel P.
Duran, Miguel A. Climent
Tyroller, Karin
Hoffman, Jason
Jacob, Natalia
Grivas, Petros
Gupta, Shilpa
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US
Carson, K.
Mahmoudpour, H.
Ike, C.
Monzon, S.
Fragkogianni, S.
Ferrer, J.
Kearney, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1215 - S1216
[10] Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)
Barthelemy, P.
Thibault, C.
Voog, E.
Eymard, J-C.
Ravaud, A.
Flechon, A.
Jaillon, C. Abraham
Hilgers, W.
Le Moulec, S.
Chasseray, M.
Pouessel, D.
Amela, Y. E.
Lorgis, V.
Nicolas, E.
Kazan, E.
Denechere, G.
Solbes, M-N.
Lambert, P.
Loriot, Y.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1341 - S1342

← 1 2 3 4 5 →